These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Mucosal vaccine delivery: Current state and a pediatric perspective. Shakya AK; Chowdhury MYE; Tao W; Gill HS J Control Release; 2016 Oct; 240():394-413. PubMed ID: 26860287 [TBL] [Abstract][Full Text] [Related]
65. Improving global vaccine accessibility. Hill AB; Kilgore C; McGlynn M; Jones CH Curr Opin Biotechnol; 2016 Dec; 42():67-73. PubMed ID: 26994376 [TBL] [Abstract][Full Text] [Related]
66. Nanotechnology solutions for mucosal immunization. Chadwick S; Kriegel C; Amiji M Adv Drug Deliv Rev; 2010 Mar; 62(4-5):394-407. PubMed ID: 19931581 [TBL] [Abstract][Full Text] [Related]
67. Novel approaches to controlled-release antigen delivery. Cohen S; Alonso MJ; Langer R Int J Technol Assess Health Care; 1994; 10(1):121-30. PubMed ID: 8157444 [TBL] [Abstract][Full Text] [Related]
68. Oral vaccines: new needs, new possibilities. Aziz MA; Midha S; Waheed SM; Bhatnagar R Bioessays; 2007 Jun; 29(6):591-604. PubMed ID: 17508389 [TBL] [Abstract][Full Text] [Related]
69. Recent advances in oral vaccine development: yeast-derived β-glucan particles. De Smet R; Allais L; Cuvelier CA Hum Vaccin Immunother; 2014; 10(5):1309-18. PubMed ID: 24553259 [TBL] [Abstract][Full Text] [Related]
70. Pulmonary vaccine delivery: a realistic approach? Tonnis WF; Kersten GF; Frijlink HW; Hinrichs WL; de Boer AH; Amorij JP J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):249-60. PubMed ID: 22856876 [TBL] [Abstract][Full Text] [Related]
71. Novel vaccination strategies for the control of mucosal infection. Husband AJ Vaccine; 1993; 11(2):107-12. PubMed ID: 8438609 [TBL] [Abstract][Full Text] [Related]
74. Microneedle arrays for vaccine delivery: the possibilities, challenges and use of nanoparticles as a combinatorial approach for enhanced vaccine immunogenicity. Rodgers AM; Cordeiro AS; Kissenpfennig A; Donnelly RF Expert Opin Drug Deliv; 2018 Sep; 15(9):851-867. PubMed ID: 30051726 [TBL] [Abstract][Full Text] [Related]
75. Virus-like particles for antigen delivery at mucosal surfaces. Schneider-Ohrum K; Ross TM Curr Top Microbiol Immunol; 2012; 354():53-73. PubMed ID: 21744306 [TBL] [Abstract][Full Text] [Related]
76. β-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination. De Smet R; Demoor T; Verschuere S; Dullaers M; Ostroff GR; Leclercq G; Allais L; Pilette C; Dierendonck M; De Geest BG; Cuvelier CA J Control Release; 2013 Dec; 172(3):671-8. PubMed ID: 24041710 [TBL] [Abstract][Full Text] [Related]
77. Mucosal vaccination--an old but still vital strategy. Długońska H; Grzybowski M Ann Parasitol; 2012; 58(1):1-8. PubMed ID: 23094329 [TBL] [Abstract][Full Text] [Related]
79. Opportunities and challenges of the pulmonary route for vaccination. Blank F; Stumbles P; von Garnier C Expert Opin Drug Deliv; 2011 May; 8(5):547-63. PubMed ID: 21438741 [TBL] [Abstract][Full Text] [Related]
80. Intranasal delivery of nanoparticle-based vaccines. Marasini N; Skwarczynski M; Toth I Ther Deliv; 2017 Jan; 8(3):151-167. PubMed ID: 28145824 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]